Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
Patients take tenofovir DF in combination with other antiretrovirals.
Age
0–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients may be eligible for this study if they:
Have completed another study on tenofovir DF without toxicity.
Are willing to use intrauterine or effective barrier methods of birth control, both men and women, during the study and for 30 days following tenofovir DF treatment.
You may not be if
Patients will not be eligible for this study if they:
Are taking drugs that may damage the kidney (nephrotoxic) including aminoglycoside antibiotics, amphotericin B, cidofovir, cisplatin, foscarnet, IV pentamidine, vancomycin, and oral or IV ganciclovir.
Are taking agents that affect kidney function, such as probenecid.
Are receiving systemic chemotherapy.
Are taking systemic corticosteroids.
Are taking experimental drugs except those that are approved by Gilead.
Are currently participating in the GS-99-908 or GS-00-912 (expanded access) studies.
